Table 1.
Clinical Features of Patients Treated with 2nd Generation TKI.
| Clinical Feature | Median [range], or No. (%) | p | |
|---|---|---|---|
| No Dose Reduction (n = 104) |
Dose Reduction/Treatment Interruption (n = 176) |
||
| Age, years | 46 [15–82] | 55 [18–80] | <0.0001 |
| Male sex | 71 (68) | 77 (44) | <0.0001 |
| Weight, kg | 81.5 [45.5–174.3] | 75.8 [47.1–179.7] | 0.07 |
| Body Surface Area, m2 | 1.99 [0.91–2.98] | 1.89 [1.24–2.95] | 0.04 |
| WBC, ×109/l | 26.5 [1–400] | 16.4 [0.7–700] | 0.04 |
| Hb, g/l | 119 [71–158] | 112 [45–212] | 0.13 |
| Platelets, ×109/l | 232.5 [3–1103] | 266 [8–2427] | 0.29 |
| Peripheral blood blasts, % | 0 [0–97] | 0 [0–82] | 0.91 |
| Bone marrow blasts, % | 2.5 [0–97] | 3 [0–88] | 0.68 |
| Time on Imatinib, months* | 24 [2–77] | 33.5 [1–77] | 0.08 |
| Previous therapies* | 2 [1–7] | 2 [1–5] | 0.67 |
| • IFN | 22 (43) | 67 (53) | 0.14 |
| • SCT | 6 (12) | 9 (7) | 0.23 |
| • TKI other than imatinib | 11 (22) | 15 (12) | 0.08 |
| Ph+ at start of 2nd-generation TKI, % | 100 [0–100] | 100 [0–100] | 0.49 |
| Stage | 0.005 | ||
| • ECP | 48 (46) | 50 (28) | |
| • LCP | 17 (17) | 58 (33) | |
| • AP | 20 (19) | 39 (22) | |
| • BP/Ph+ ALL | 19 (18) | 29 (17) | |
| Time from diagnosis to 2nd-generation TKI therapy, years | 1 [0–19] | 4 [0–19] | 0.0002 |
| TKI received | <0.0001 | ||
| • Dasatinib | 38 (37) | 113 (64) | |
| • Nilotinib | 66 (63) | 63 (36) | |
*
Only for patients not in frontline therapy (N=177; no dose reduction/interruption = 51; dose reduction/interruption = 126)
TKI,; IFN, interferon; SCT, stem cell transplantation; ECP, early chronic phase; LCP, late chronic phase; AP, acute phase; BP/Ph+ ALL, blast phase/ Philadelphia positive acute lymphoblastic leukaemia